Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIDORA: Dazodalibep in Rheumatoid Arthritis
NCT04163991Phase 2Completed
- Sponsor
- Amgen
- Start
- Dec 2019
- Primary completion
- Dec 2021
- Modality
- Fc-Fusion Proteins
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of dazodalibep in rheumatoid arthritis (RA) (5 arms), sponsored by Amgen. Primary endpoints: Change From Baseline in Disease Activity Score 28-Joint Count C-Reactive Protein at Day 113 and Treatment-Emergent Adverse Events at Day 309. Started Dec 2019; status: completed.
02
Drugs
dazodalibep
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04163991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04163991.